HOME >> BIOLOGY >> NEWS
Novel Two-Antibody Strategy To Fight Cancer Awarded Patent

Researchers at the University of Pennsylvania Medical Center today were awarded patent number 5,824,311 for a new technology that has shown the potential in laboratory studies to cure breast and other major cancers linked to certain abnormal genes.

Broadly viewed, the approach targets cancer-causing receptor molecules found on the surface of tumor cells with two different antibodies that bind to the molecules, fatally disabling the receptor's activity and leading to the cancer cell's death.

The specific application of the concept detailed in the patent employs a pair of antibodies against a receptor protein called p185. The p185 protein assembles into a two-protein receptor complex thought to be involved in stimulating the uncontrolled growth of a number of dangerous cancers, including those of the breast and the pancreas. Instructions for producing the p185 protein in the cell are encoded by a gene known as neu.

The recently approved anti-breast-cancer drug Herceptin also acts on the receptor produced by the neu gene but brings only one antibody to bear on it. Experiments in rodent models, however, showed that a two-antibody strategy was significantly more powerful.

"In our two-antibody studies, we were able to achieve cures of tumors as opposed to simply reducing tumor growth," says Mark I. Greene, MD, PhD, a professor of pathology and laboratory medicine in whose laboratory the work was conducted. "In our experience, a single antibody against the receptor only diminishes the growth of tumor cells, whereas two antibodies disable the receptor so effectively that the cells perish."

Receptor proteins are convoluted structures with many sites -- called epitopes -- to which a wide array of antibodies can bind. It is possible for some of these sites not to be involved in the activity of the protein. Also, antibodies that bind in different ways to the same site can limit each other's effectiveness. Signif
'"/>

Contact: Franklin Hoke
hokef@mail.med.upenn.edu
215-349-5659
University of Pennsylvania School of Medicine
20-Oct-1998


Page: 1 2

Related biology news :

1. Novel IBD therapeutic approaches reported from Washington Univ., Barcelona, LSU at APS meeting
2. Novel therapeutic bortezomib moves to phase II trial in lung cancer patients
3. Novel approaches to current cellular therapies continue progress toward disease prevention
4. Novel therapies show promise against myeloid leukemia
5. Novel sensors help clear the air
6. Fox Chase Cancer Center study: Novel DNA-repair gene mutation can cause resistance to cancer drugs
7. Novel proteins designed that block inflammation regulator associated with rheumatoid arthritis
8. Novel therapeutic target identified in fight against Rheumatoid Arthritis
9. Novel bacterium detoxifies chlorinated pollutants
10. Novel flu vaccine shows promise in mice
11. Novel gene therapy on the horizon, says Brenner Childrens Hospital pediatrician

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Novel Two Antibody Strategy Fight Cancer Awarded Patent

(Date:4/16/2014)... museum collections two new species of yellow-shouldered bats have been unearthed ... Field Museum of Natural History and described in the open access ... the genus Sturnira are part of a recent discovery ... third one still waiting to be officially announced. , Up until ...
(Date:4/16/2014)... Centre INRSInstitut Armand-Frappier has just received a research grant from ... nearly US$600,000. The 5-year grant is to pursue cutting-edge research ... explore their biomedical potential in the field of oncology as ... a grant at this level is an accomplishment in itself," ...
(Date:4/16/2014)... Arkin, director of the Physical Biosciences Division of Lawrence ... is recognized as a leading authority on the evolutionary ... application to systems and synthetic biology, has been named ... Lawrence Award by U.S. Energy Secretary Ernest Moniz. The ...
Breaking Biology News(10 mins):Two new species of yellow-shouldered bats endemic to the Neotropics 2High-level NIH grant goes to professor Nicolas Doucet of INRS 2Berkeley Lab's Adam Arkin wins 2013 Lawrence Award 2Berkeley Lab's Adam Arkin wins 2013 Lawrence Award 3
(Date:1/14/2014)... MA (PRWEB) January 14, 2014 iLab Solutions, ... Detwiler as the new Director of Product Strategy. In this ... well as iLab sub-teams to guide in the development of ... iLab provides the maximum possible benefit to the scientific community ...
(Date:1/14/2014)... WESTBOROUGH, Mass. , Jan. 14, 2014  RXi ... on discovering, developing and commercializing innovative therapies addressing ... announced that it received the Notice of Allowance ... on its unique self-delivering RNAi compounds (sd-rxRNA®), for ...
(Date:1/14/2014)... , Jan. 14, 2014   Kinaxis ®, provider of ... and sales and operations planning ( S&OP ) service, is ... Summit , which will be held at the Hilton San ... join Kinaxis customer Elisabeth Kaszas , Director of Supply ...
(Date:1/14/2014)... Kerr Corporation, a leading manufacturer of innovative ... information about dual arch impressions on its dental blog. ... the blog entry serves up a list of tips to ... demonstration by Dr. David Little as he crafts a porcelain ...
Breaking Biology Technology:iLab Solutions Announces Michelle Detwiler as the New Director of Product Strategy 2RXi Pharmaceuticals Receives US Notice of Allowance for a Key Patent Relating to its Self-Delivering Technology with sd-rxRNAs targeting CTGF, including RXI-109, for the Treatment of Fibrotic Disorders 2RXi Pharmaceuticals Receives US Notice of Allowance for a Key Patent Relating to its Self-Delivering Technology with sd-rxRNAs targeting CTGF, including RXI-109, for the Treatment of Fibrotic Disorders 3Event Alert: Kinaxis Customer to Present at the Biomanufacturing Summit "Supply Chain: Improving Network Effectiveness" 2
Cached News: